Delivery Order SPE2DB24D1021-SPE2DB25FEYXH
- Not listed
- The Defense Logistics Agency awarded a $2,999.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion, a prescription ophthalmic medication used to treat dry eye disease. The contract, which carries an ultimate completion date of September 18, 2025, represents a non-competitive delivery against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $1,006.64 to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion (60 count) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. RESTASIS is a brand-name ophthalmic emulsion used to treat dry eye disease, a condition prevalent among...
- The Defense Logistics Agency awarded a $3,018.16 delivery order to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $1,660.46 to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion (60-unit supply) on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed price delivery order carries no set-aside designation and represents a competitive award through open procurement channels. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of RESTASIS 0.05% Eye Emulsion in 60-count units. This is a competitively awarded, firm fixed-price delivery order valued at $1,862.70 with no set-aside designation, with an ultimate completion date of July 23, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $23,799.46 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (60 count) on May 8, 2025, with completion scheduled for May 9, 2025. This firm fixed-price contract, which was competitively awarded with no set-aside designation, will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Restasis is a prescription ophthalmic medication used to treat dry eye disease, representing part of...
- The Defense Logistics Agency awarded a delivery order valued at $2,929.30 to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion (30 count) on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a single transaction under the company's broader federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $18,550.26 to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion (60 count) on September 11, 2025, with an ultimate completion date of September 12, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $14,980.58 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (60-count units) on September 4, 2025, with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of the vendor's extensive pharmaceutical supply relationship with the federal government. The product will be delivered to...
- The Defense Logistics Agency awarded a $1,293.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (60-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside contract was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FEYXHDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,875.74 to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion, a prescription ophthalmic medication used to treat dry eye disease. The contract, awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed-price delivery under a non-set-aside competitive procurement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle valued through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through its DLA Medical Supply Chain contracts, which demonstrate the company's capability to fulfill diverse pharmaceutical requirements ranging from specialty medications to vaccines and medical devices across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.9k | 7/22/25 |